As you may know, the U.S. Food and Drug Administration (FDA) has been reviewing an application for FILSPARI (sparsentan) for the treatment of focal segmental glomerulosclerosis (FSGS). The initial date for the FDA to make a decision on this drug was January 13, 2026. On that date, the FDA issued what is called a major amendment, which means the review process will take more time.

The purpose of this FSGS Community Town Hall is to help provide more details about this decision and answer your questions related to this update. It will be led by NephCure Specialists Dr. Matthias Kretzler and Howard Trachtman.

You can expect the town hall to focus on:

  • Sharing more information on the drug development and FDA review process
  • Explaining how this may impact you and your family
  • Listening to our FSGS community and answering your questions
  • Providing ways that you can make your voice heard by decision-makers

Please submit any questions that you’d like our hosts to answer on the registration page. We look forward to seeing you soon.

To read our letter to the NephCure Community about this update, click here.

 

Share this